Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This is an 18-week open-label, multicenter study to evaluate the efficacy and tolerability of
CEP-701 (lestaurtinib) treatment in patients with Polycythemia Vera (PV) and patients with
Essential Thrombocytosis (ET).